AUPH Aurinia Pharmaceuticals Inc

7.00
+0  (1%)
Previous Close 6.92
Open 6.99
Price To book 10.16
Market Cap 374.00M
Shares 53,428,000
Volume 5,322,190
Short Ratio 0.28
Av. Daily Volume 8,821,590

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

48-week data from open-label AURION study presented March 27, 2017 - primary endpoint met.
Voclosporin - AURION trial
Lupus
Phase 2b data released August 2016. Primary endpoint met but with high number of deaths. Further data released March 1, 2017 - no additional deaths and endpoints met. Phase 3 trial to be initiated 2Q 2017.
Voclosporin - AURA trial
Lupus

Latest News

  1. Today's Research Reports on Stocks to Watch: Aurinia Pharmaceuticals and Immune Pharmaceuticals
  2. Aurinia Releases Additional 48-Week Data from the AURA-LV Study During Late-Breaking Session at the National Kidney Foundation 2017 Spring Clinical Meetings
  3. This Trading-Range Action Is Not Offering Much
  4. Implied Volatility Surging for Aurinia Pharmaceuticals(AUPH) Stock Options
  5. Aurinia Completes Licensing Deal with Merck Animal Health for Its Nanomicellar Formulation of Voclosporin for the Treatment of Canine Dry Eye Syndrome
  6. Aurinia to Host Investor Event and Webcast on April 20th in Orlando, FL
  7. Aurinia Pharmaceuticals Plans to Take a Big Step Forward
  8. Here's Why Aurinia Pharmaceuticals Rose as Much as 10.8% This Morning
  9. Aurinia Pharmaceuticals Jumps on Phase 3 Planned Trial
  10. Aurinia Plans Phase 3 Study for Lupus Drug
  11. Aurinia Announces Development Plans for Voclosporin in Europe and Japan
  12. Q1 Roundup: Winners and Losers of Biotech Sector
  13. BC Tech Fund to Invest in Lumira Capital IV, L.P.
  14. Aurinia Pharmaceuticals: Where to From Here?
  15. Aurinia's Voclosporin Reports Positive Results
  16. Aurinia Highlights 48-Week Data from Open-Label AURION Study at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017)
  17. 3 Hot Biotech Stocks Now
  18. Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?
  19. Financials of Aurinia Pharmaceuticals and Catalyst Pharmaceuticals are Getting Stability
  20. Aurinia Closes US$173.1 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares